Safety profile of enantiomers vs. racemic mixtures: it's the same?

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT The physicochemical properties of racemates and stereoisomers of medicines can differ significantly, and this may affect the side-effect profile in addition to the pharmacokinetics and intended pharmacology. WHAT THIS STUDY ADDS This is a study to investigate the profile of adverse drug reactions of racemic and enantiomeric forms of drugs. Our data suggest differences in the safety profile for ofloxacin and omeprazole. This area requires more work to investigate this for other compounds. AIMS The objective was to investigate the safety profile of four drugs marketed as racemic and enantiomeric forms in France. METHODS Data from the French PharmacoVigilance Data Base (January 2005 to June 2010) were analysed for four pairs of racemic/isomeric drugs. A case-noncase approach was used to measure the disproportionality of combination between adverse drug reaction (ADR) and exposure to drug. RESULTS No significant difference in the number of ADRs was observed between Rac-cetirizine/(R)-cetirizine or Rac-citalopram/(S)-citalopram pairs. (S)-Omeprazole induced more haematological effects than Rac-omeprazole. Rac-Ofloxacin induced more haematological, renal and neuropsychiatric ADRs than (S)-ofloxacin, whereas levofloxacin was associated with more reports of musculoskeletal ADRs. CONCLUSIONS The profile of ADRs could differ for some drugs marketed as racemic and enantiomeric forms. Further studies would be necessary to confirm these data.

[1]  Maryse Lapeyre-Mestre,et al.  Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. , 2011, British journal of clinical pharmacology.

[2]  Bernard Bégaud,et al.  Rates of spontaneous reporting of adverse drug reactions in France. , 2002, JAMA.

[3]  Silas W Smith.  Chiral toxicology: it's the same thing...only different. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  B. Bégaud,et al.  Is reporting rate a good predictor of risks associated with drugs? , 1999, British journal of clinical pharmacology.

[5]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[6]  N. Moore,et al.  Spontaneous Reporting—France , 2002 .

[7]  E. G. Brown,et al.  The medical dictionary for regulatory activities (MedDRA) : a survey of regulatory authorities' approaches to implementation , 1998 .

[8]  E. Brown,et al.  The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.

[9]  D. Bachir,et al.  No effect of CYP450 and P‐glycoprotein on hydroxyurea in vitro metabolism , 2010, Fundamental & clinical pharmacology.

[10]  H. Hakusui,et al.  Enantioselective disposition of ofloxacin in humans , 1991, Antimicrobial Agents and Chemotherapy.

[11]  H. Hakusui,et al.  Stereoselective glucuronidation of ofloxacin in rat liver microsomes. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[12]  T. Andersson,et al.  Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole , 2001, Clinical pharmacokinetics.